Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeMEDTRONIC plcFive-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven...

Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting

April 26, 2017

Five-Year Data from Global ENGAGE Registry 
Support Endurant II’s Market-Leading Position Worldwide

Medtronic plc today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time at the 2017 Charing Cross Symposium in London.

The ENGAGE registry evaluated more than 1,200 patients. The five-year data, which included imaging follow up from approximately 500 of these patients, showed a 97.8 percent freedom from aneurysm-related mortality (ARM) and a compelling 89.4 percent stable or decrease diameter AAA sac at five years. The data demonstrated an 84.3 percent freedom from secondary endovascular procedures.

“Out to five years, the ENGAGE data showed low ARM and secondary procedure rates. This further demonstrates both the benefit of the technique used with Endurant as well as the durability of the graft itself,” said ENGAGE investigator Philippe Cuypers, M.D., Ph.D., vascular surgeon, Catharina Hospital in Eindhoven, The Netherlands, who presented the data. “The clinical rigor and scope of the ENGAGE registry has made it a valuable data set that represents the types of challenging anatomies physicians encounter in daily clinical practice.”

ENGAGE represents the most robust post-market registry ever initiated in the study of endovascular aortic repair (EVAR) with 79 sites in 30 countries. The ENGAGE registry was initiated less than one year post CE Mark and has clinical follow up out to 10 years, further demonstrating the Medtronic commitment to long-term clinical excellence. The goal of ENGAGE remains to gather evidence in a real-world patient population, including patients with challenging anatomy who have historically been difficult to treat, and are associated with limited eligibility for endovascular repair and higher rates of secondary interventions. A rigorous monitoring protocol has resulted in a clinical follow-up compliance of more than 90 percent and imaging compliance of more than 75 percent at five years.

Data from ENGAGE Featured in Other Key Presentations at Charing Cross
The Endurant stent graft system was also featured in an additional presentation that showcases how the ENGAGE data are being used to inform clinician’s treatment decisions following EVAR procedures. On Wednesday, April 26, 2017, Peter Holt, M.D., senior lecturer and honorary consultant in vascular surgery at St. George’s University of London presented the design of the LEAR analysis, which aims to reduce long-term aortic risk using a modified clinical surveillance program that more accurately portrays reintervention risk.

As demonstrated in Prof. Hence Verhagen, M.D., Ph.D., presentation entitled “Safety Considerations with Hostile Neck 10-15mm,” on April 26, 2017, Endurant continues to demonstrate durable results across a range of patient anatomies, including patients with more hostile aortic necks, which have historically been associated with limited eligibility for endovascular repair and higher rates of adverse events.

“Medtronic aims to increase access to treatment for patients with Aortic disease. This goal has been reinforced by our commitment to developing robust clinical programs – such as the ENGAGE registry – that help clinicians identify durable treatment options,” said Daveen Chopra, vice president and general manager of the Aortic business in Medtronic’s Cardiac and Vascular Group. “In fact, we are leveraging our strong Endurant stent graft data for a pilot risk-share program in the U.S. that has been designed to help decrease customer costs associated with secondary EVAR interventions.”

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About the Endurant II/IIs Stent System
Selected for nearly one of every two endovascular abdominal aortic aneurysm (AAA) repairs globally and more than 280,000 successful implants, the Endurant system received the CE (Conformité Européenne) Mark in June 2008. U.S. Food and Drug Administration (FDA) approval was received in December 2010. The Endurant stent graft system is approved outside of the U.S. for use in patients with AAA neck lengths >=10 mm and <=60° infra-renal angulation and >=15mm with <=75° infra-renal angulation. In the U.S., the Endurant stent graft system is indicated for necks >=10 mm and <=60° infra-renal angulation.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy